Continuity Biosciences appoints Vicky Papoutsis
Analysis based on 6 articles · First reported Jul 30, 2026 · Last updated Jul 30, 2026
This board appointment is a minor corporate governance event with limited direct market impact. It signals Continuity Biosciences' focus on strategic partnerships as it advances its pipeline, which may positively influence investor sentiment in the long term.
Continuity Biosciences, a clinical-stage biotechnology company developing precision drug delivery platforms, announced the appointment of Vicky Papoutsis to its Board of Directors on July 30, 2026. Papoutsis brings over 25 years of biopharmaceutical business development and corporate strategy experience, currently serving as Executive Vice President and Chief Strategy Officer at Bicara Therapeutics. The appointment comes as Continuity advances its clinical and preclinical programs, including a lead pancreatic cancer program now in the clinic, and expands its partnering activity. Papoutsis has negotiated more than 30 strategic transactions and built three private equity-backed biosciences startups. The Board also includes Michael Fowler (CEO of Affordable Housing Partners, a Berkshire Hathaway subsidiary), Monica Reed (President and CEO of UChicago Medicine AdventHealth Great Lakes Region), Josephine M. Torrente (former partner at Hyman, Phelps & McNamara), Ramakrishna Venugopalan (Co-Founder and CEO), Allen Weiss (former President of Worldwide Operations for The Walt Disney Company — Disney Experiences), and Robert Whitehead (Co-Founder and Executive Chairman, also Chairman of Sprout Pharmaceuticals).
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard